U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07108894) titled 'A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants' on July 24.
Brief Summary: This study aims to assess the safety and tolerability of ABL575 in healthy participants following single-dose administration (SAD), in comparison to a placebo
Study Start Date: July 25
Study Type: INTERVENTIONAL
Condition:
Healty Volunteers
Intervention:
BIOLOGICAL: ABCL575
Participants will receive SC injection of ABCL575
BIOLOGICAL: Placebo (Normal Saline 0.9%)
Participants will receive SC injection of placebo (Normal Saline 0.9%)
Recruitment Status: RECRUITING
Sponsor: AbCellera Biologics Inc.
Disclaimer:...